Mirum Pharmaceuticals Inc... (MIRM)
NASDAQ: MIRM
· Real-Time Price · USD
72.76
-0.81 (-1.10%)
At close: Sep 26, 2025, 3:59 PM
73.19
0.59%
After-hours: Sep 26, 2025, 04:15 PM EDT
Mirum Pharmaceuticals Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue | 127.78M | 111.58M | 177.19M | 90.3M | 77.76M | 68.92M | 69.55M | 47.73M | 32.5M | 29.1M | 27.91M | 18.78M | 17.48M | 10.89M |
| Product Revenue Growth | +14.52% | -37.03% | +96.22% | +16.13% | +12.83% | -0.92% | +45.74% | +46.86% | +11.68% | +4.27% | +48.59% | +7.41% | +60.52% | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|
| Rest Of World Revenue | 32.25M | 24.66M | 79.08M | 16.4M | 12.68M | 12.81M |
| Rest Of World Revenue Growth | +30.77% | -68.81% | +382.27% | +29.31% | -0.98% | n/a |
| United States Revenue | 95.53M | 86.92M | n/a | 73.91M | 65.08M | 56.11M |
| United States Revenue Growth | +9.91% | n/a | n/a | +13.56% | +15.98% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 63.29M | 57.71M | 56.83M | 50.55M | 49.21M | 45.64M | 46.18M | 36.53M | 32.95M | 30.22M | 26.47M | 22.51M | 20.97M | 19.12M | 19.04M | 17.35M | 13.35M | 9.48M | 7.22M | 5.73M | 5.04M | 4.69M | 4.28M | 3.71M | 2.44M | 1.32M | 805.5K | 62K |
| Selling, General, and Administrative Revenue Growth | +9.67% | +1.54% | +12.43% | +2.72% | +7.82% | -1.18% | +26.43% | +10.86% | +9.03% | +14.17% | +17.57% | +7.36% | +9.69% | +0.43% | +9.69% | +29.96% | +40.87% | +31.20% | +26.05% | +13.69% | +7.46% | +9.68% | +15.37% | +51.66% | +85.09% | +64.00% | +1199.19% | n/a |
| Research and Development Revenue | 46.07M | 46.04M | 44.03M | 31.71M | 32.67M | 32.22M | 30.84M | 26.12M | 22.01M | 23.55M | 31.11M | 26.22M | 25.43M | 24.09M | 27.77M | 30.47M | 35.05M | 38.13M | 29.73M | 15.98M | 18.55M | 17.34M | 14.38M | 12.16M | 11.59M | 4.86M | 25.23M | 3K |
| Research and Development Revenue Growth | +0.05% | +4.58% | +38.84% | -2.94% | +1.40% | +4.48% | +18.09% | +18.67% | -6.54% | -24.30% | +18.64% | +3.09% | +5.58% | -13.27% | -8.85% | -13.06% | -8.09% | +28.29% | +85.97% | -13.86% | +7.01% | +20.58% | +18.27% | +4.92% | +138.31% | -80.72% | +840850.00% | n/a |